Back to search

University of Strathclyde

The design, synthesis and optimisation of small molecule ERAP1 inhibitors

Abstract

dc:description.abstract

Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) is an intracellularaminopeptidase based in the endoplasmic reticulum. Peptides are cleaved by ERAP1then subsequently presented on the cell surface for signalling with the immune system.Inhibition of ERAP1 modulates the adaptive immune response and therefore hasindications as a target for cancer or autoimmune diseases.Described herein is the design and syntheses of three distinct chemical series, withinthe hit to lead drug discovery stage, which inhibit ERAP1: the Benzazepine series,Cyclohexyl Acid series and Proline series [see Table 1 in thesis]. These series were optimised interms of potency, physicochemical properties and ligand efficiencies. Structure-baseddrug design, based on ERAP1 X-ray crystallography, was used as the primary tool tooptimise potency by achieving new protein-ligand interactions with ERAP1.Physicochemical property optimisation was guided by literature best practices toreduce the probability of developability risks such as poor solubility and highmetabolic clearance.For the Benzazepine Series, although progress was achieved in terms of ERAP1potency and physicochemical property optimisation, a data-driven decision was madeto pause the chemistry on the series due to the shortcomings of murine EndoplasmicReticulum Aminopeptidase Associated with Antigen Processing (ERAAP1) activity.Progress was also made in the Proline series in terms of biochemical potency, but theseries generally showed poor cellular activity. For the Cyclohexyl Acid series, highlyligand efficient examples in a desirable physicochemical property space weredeveloped, with several examples exhibiting subnanomolar cellular potency. SeveralCyclohexyl Acid compounds were tested against closely related enzymes EndoplasmicReticulum Aminopeptidase 2 (ERAP2) and Insulin-Regulated Aminopeptidase(IRAP), and were found to be highly selective for ERAP1 over these other enzymes.As a result of satisfying all project objectives, the Cyclohexyl Acid series transitionedinto Lead Optimisation for further development.

Degree

thesis:*
Name dc:type.qualificationname
phd
Level dc:type.qualificationlevel
doctoral-pg
Grantor dc:publisher.institution
University of Strathclyde
Year dc:date.issued
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Hryczanek, Ross Peter
Advisors dc:contributor.advisor
  • Reid, Marc
  • Palmer, David
  • Lindsay, David
  • Tomkinson, Nick
Author Identifier dc:creator.authoridentifier
  • 201885374

Rights

Identifiers

dc:identifier.*
Identifier
T17251

Chain of custody

source
Harvested from
University of Strathclyde
Base URL
stax.strath.ac.uk/catalog/oai
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Hryczanek, Ross Peter. The design, synthesis and optimisation of small molecule ERAP1 inhibitors. doctoral-pg thesis, University of Strathclyde, 2023. https://stax.strath.ac.uk/concern/theses/pn89d723w